Ruxolitinib (Jakavi)

Ruxolitinib for myelofibrosis

The aim of the present study was to assess the beneficial and harmful effects of ruxolitinib in patients with myelofibrosis (MF). The Cochrane databases, PubMed and Embase were searched for studies published up to October 2012. Randomised controlled trials assessing ruxolitinib versus a placebo or the best available therapy in patients with MF were included. Two trials randomised 528 patients w...

Ruxolitinib for essential thrombocythemia?

Ruxolitinib for myelofibrosis

Myelofibrosis (MF), a myeloproliferative neoplasm, is a disease associated with a significant burden of symptoms, shortened survival and an array of standard treatment regimens which have historically lacked impact and efficacy. The discovery in 2005 of the highly prevalent JAK2V617F-activating tyrosine kinase mutation, strongly associated with myeloproliferative neoplasms, led to the rapid dev...

Ruxolitinib in Myelofibrosis and Polycythemia Vera

JAK inhibitors and myelofibrosis, Einstein and ruxolitinib.

This year marks a decade since the original descriptions of the JAK2 mutation in myeloproliferative neoplasms. 4 In the intervening years we have witnessed this finding influencing diagnostic processes, prognostic determination and more recently therapeutics. Whilst some perhaps naively anticipated that the benefits of JAK2 as a therapeutic target would parallel those of BCR/ABL inhibitors we h...